Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

Sanofi hires former GSK development head Chris Corsico as global R&D head, replacing Dietmar Berger who left for Gilead. Move aligns with €2B R&D investment strategy.

FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with ...

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

Important research news last week included UK pharma major AstraZeneca releasing encouraging results from the CALYPSO Phase ...

This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease ...

Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio Inc. for $600 million upfront ...

French drugmaker Sanofi has agreed to buy autoimmune disease therapy DR-0201 developed by Serbian-founded, US-based biotechnology firm Dren Bio, the two compani ...

The consumer price index (CPI) of Bosnia's Federation increased by 3.4% year-on-year in February, after growing by 3.3% <a ...